Arcana Institute (INAR) is now part of Certara, a global leader in model-informed drug development and regulatory science.

Arcana Institute, together with Analytica Laser and other companies acquired by Certara, provides support for drug development through the product’s full life cycle, from clinical trial planning & design, drug registration, Real World Data, strategic support in HEOR and Market Access, up to reimbursement and beyond.

Certara’s staff includes over 700 experts in more than 20 offices worldwide!

Together, we are creating innovative analytical methods to provide our partners with the highest-quality scientific evidence in safety, clinical efficacy and effectiveness for medical technologies.

find out more

Business Partners

Cooperative Institutions


17 July 2018

Analysis of the Reimbursement Decision-Making Practice in Poland (July 2018)

The latest results of the periodic Analysis of the Reimbursement Decision-Making Practice of AHTAPol and the Minister of Health The results include the notice of the Minister of Health from 29 June  more...
13 July 2018

The most notable changes and challenges in Poland

Session Summary from VI HTA Symposium (11-12 June 2018) The panelists: Marcin Czech, Roman Topór-Mądry, Dominik Dziurda, Ewa Warmińska, Tomasz Bochenek, Agnieszka Pachciarz The moderator: Jacek Walczak   The  more...
3 July 2018

VI HTA Symposium 2018 in Krakow

  Arcana Institute hosted its annual HTA Symposium in Krakow, bringing together recognized experts from the public and private sectors to discuss current events and challenges taking place in Poland  more...